GlobalData, the industry analysis specialist, has released its new report, “Irritaable Bowel Syndrome(IBS) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source ofinformation and analysis on the global IBS market. The report identifies the key trends shaping and driving theglobal IBS market. The report also provides insights on the prevalent competitive landscape and the emergingplayers expected to significantly alter the market positioning of the current market leaders. Most importantly,the report provides valuable insights on the pipeline products within the global IBS sector. This report is builtusing data and information sourced from proprietary databases, primary and secondary research and in-houseanalysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global IBS market was worth $1.7 billion in 2009. It isforecast to grow at a Compound Annual Growth Rate (CAGR) of 6% for the next seven years, to reach $2.72billion by 2017. The high projected growth rate is primarily attributable to a strong pipeline. Increases in theprevalence of the disease and the availability of new first-in-class therapies with better safety and efficacyprofiles are expected to drive the growth of the IBS market Scope The report provides information on the key drivers and challenges of the IBS market. Its scope includes: Annualized global IBS market revenues data from 2001 to 2009, forecast for eight years to 2017. Pipelineanalysis data providing a split across the different phases, mechanisms of action being developed andemerging trends. Pipeline candidates fall under major therapeutic classes such as Serotonin receptor targets,Guanylate cyclase type C receptor agonist, NK receptor targets, CRF1 receptor agonist. Analysis of thecurrent and future competition in the global IBS market. Key market players covered are Ironwood
Pharmaceuticals and Forest Laboratories, Tioga Pharmaceuticals, Procter & Gamble (P&G), LexiconPharmaceuticals, Salix Pharmaceuticals and Astellas Pharma. Insightful review of the key industry drivers,restraints and challenges. Each trend is independently researched to provide a qualitative analysis of itsimplications. Key topics covered include strategic competitor assessment, market characterization, unmetneeds and the implications for the IBS therapeutics market Reasons to buy The report will enhance your decision making capability. It will allow you to: Develop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies and by identifying the companies with the most robust pipeline. Develop business strategies byunderstanding the trends shaping and driving the global IBS market. Drive revenues by understanding the keytrends, innovative products and technologies, market segments and companies likely to impact the global IBSmarket in future. Formulate effective sales and marketing strategies by understanding the competitivelandscape and by analyzing the performance of various competitors. Identify emerging players withpotentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that presentmaximum opportunities for consolidations, investments and strategic partnerships. What’s the next bigthing in the global IBS market landscape? - Identify, understand and capitalize
1 Table Of Contents 31.1 List Of Tables 51.2 List Of Figures 5
2 Irritable Bowel Syndrome Introduction 62.1 Globaldata Pipeline Report Guidance 6
3 Irritable Bowel Syndrome: Market Characterization 73.1 Irritable Bowel Syndrome Market Size 73.2 Irritable Bowel Syndrome Market Forecast And Cagr 73.3 Drivers And Barriers For The Irritable Bowel Syndrome Market 83.3.1 Drivers 83.3.2 Restraints 93.4 Opportunity And Unmet Need 103.5 Key Takeaway 11
4 Irritable Bowel Syndrome Market: Competitive Assessment 124.1 Overview 124.2 Strategic Competitor Assessment 124.2.1 Lotronex (alosetron) 134.2.2 Amitiza (lubiprostone) 154.2.3 Colpermin (peppermint Oil) 174.2.4 Bentyl (dicyclomine Hydrochloride) 184.3 Key Takeaway 20
5 Irritable Bowel Syndrome Market: Pipeline Assessment 215.1 Overview 215.2 Strategic Pipeline Assessment 215.2.1 Technology Trends Analytical Framework 215.3 Irritable Bowel Syndrome Promising Drugs Under Clinical Development 23
5.4 Drugs Under Clinical Development 245.4.1 Linaclotide (linaclotide Acetate) 245.4.2 Asimadoline 255.4.3 Xifaxan (rifaximin) 265.4.4 Lx-1031 275.4.5 Ym060 (ramosetron Hydrochloride) 285.5 Irritable Bowel Syndrome Market Clinical Pipeline By Mechanism Of Action 305.6 Irritable Bowel Syndrome Pipeline Pipeline By Clinical Phases Of Development 315.6.1 Irritable Bowel Syndrome Market Phase Iii Clinical Pipeline 315.6.2 Irritable Bowel Syndrome Market Phase Ii Clinical Pipeline 325.6.3 Irritable Bowel Syndrome Market Phase I Clinical Pipeline 335.6.4 Irritable Bowel Syndrome Market Preclinical Pipeline 335.6.5 Irritable Bowel Syndrome Market Discovery 335.6.6 Irritable Bowel Syndrome Market Status Unknown 335.7 Discontinued / Suspended Drugs For Irritable Bowel Syndrome 345.8 Key Takeaway 34
6 Irritable Bowel Syndrome Market: Implications For Future Market Competition 35
7 Irritable Bowel Syndrome Market: Future Players In The Irritable Bowel Syndrome Market 377.1 Introduction 377.2 Ironwood Pharmaceuticals And Forest Laboratories 377.2.1 Company Overview 377.2.2 Ibs Pipeline Portfolio 387.3 Tioga Pharmaceuticals 407.3.1 Company Overview 407.3.2 Ibs Pipeline Portfolio 407.4 Alimentary Health Ltd And P&g 417.4.1 Company Overview 417.4.2 Ibs Pipeline Portfolio 417.4.3 Bifantis (bifidobacterium Infantis 35624) 427.5 Lexicon 437.5.1 Company Overview 437.5.2 Ibs Pipeline Portfolio 437.5.3 Lx-1031 437.6 Salix Pharmaceuticals 447.6.1 Overview 447.6.2 Ibs Pipeline Portfolio 447.6.3 Xifaxan (rifaximin) 447.7 Astellas Pharma 457.7.1 Overview 457.7.2 Ibs Pipeline Portfolio 46
8 Ibs Market: Appendix 488.1 Definitions 488.2 Abbreviations 488.3 Research Methodology 498.3.1 Coverage 498.3.2 Secondary Research 49
8.3.3 Forecasting 498.3.4 Primary Research 538.3.5 Expert Panels 538.4 Contact Us 538.5 Disclaimer 538.6 Sources 54
About Us: MarketResearchMoz "Make available information to the professionals for decision making, acrossindustries and vertical’s by offering fast, efficient and hassle free online purchasing medium".Source: http://www.marketresearchmoz.com/therapeutic-area/irritable-bowel-syndrome-pipeline-assessment-41503.pdf
Browsable and searchable archive of 2009 Kansas Statutes Annotated (K.S.A.) : Schools : Technology Education And Virtual Schools Statute 72-3715: Same; determining full-time equivalent enrollment; state aid; virtual school fund. (a) In order to be included in the ful -time equivalent enrol ment of a virtual school, a pupil shal be in attendance at the virtual school on (1) a single sch
Emergency Medical Services Division Public Health – Seattle / King County 401 5th Avenue, Suite 1200 Seattle, Washington 98104-2333 (206) 296-4693 Altered Mental States Introduction Consciousness is being awake and aware of your surroundings, thoughts, ideas and emotions. Injury or illness can bring about varying degrees of consciousness ranging from confused to lethargic to unconsc